Study on clinical prognosis among ETV6/RUNX1 positive childhood B-precursor acute lymphocyte leukemia
10.3969/j.issn.1000-3606.2016.05.001
- VernacularTitle:ETV6/RUNX1阳性儿童急性B系淋巴细胞白血病临床预后研究
- Author:
Xingwei WANG
;
Benshang LI
;
Shuhong SHEN
;
Jing CHEN
;
Jingyan TANG
- Publication Type:Journal Article
- Keywords:
ETV6/RUNX1;
fusion gene;
acute lymphocytic leukemia;
recurrent;
childhood
- From:
Journal of Clinical Pediatrics
2016;34(5):321-325
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the incidence of the ETV6/RUNX1 fusion gene among Chinese pediatric patients with B-ALL and its effect on the prognosis. Methods A total of 723 patients with B-ALL from January 1, 2007 to December 31, 2014 were enrolled in this study. All patients were detected ETV6/RUNX1 fusion gene by FISH. Clinical data and ETV6/RUNX1 were combined to analyze the clinical prognosis. Results Among the 723 patients, 151 were with ETV6/RUNX1 positive B-ALL, accounting for approximately 20.89%(151/723) of B-precursor cases;91 patients were with recurrence, including 10 patients with ETV6/RUNX1 positive B-ALL, and the recurrence rate of ETV6/RUNX1 positive B-ALL was 10.99%(10/91). Among 10 recurrent patients with ETV6/RUNX1 positive B-ALL, 9 patients relapsed more than 300 days later after diagnosis, while the recurrence times among the patients with ETV6/RUNX1 negative was very different. Although the recurrence times between the two groups showed no signiifcant difference (P?=?0.09), the recurrence times of ETV6/RUNX1 positive patients were mainly found at the end of clinical chemotherapy, while the recurrence time of ETV6/RUNX1 negative patients were mainly at maintaining chemotherapy period, there was a signiifcant difference between the distribution of recurrence time (P?
